Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 3:43 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 680 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Steatosis Clear all
Completed Phase 2 Interventional Results available

Alternate Dosing Study of MK-6024 in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) (MK-6024-016)

NCT06482112
View directory record Official record
Conditions
Metabolic Dysfunction-Associated Steatotic Liver Disease, Non-alcoholic Fatty Liver Disease, Nonalcoholic Fatty Liver Disease, Liver Disease
Interventions
Efinopegdutide
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
36
States / cities
Chandler, Arizona • Peoria, Arizona • Tucson, Arizona + 27 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Oct 21, 2026, 3:43 PM EDT
Recruiting Phase 2 Interventional

Digoxin In NASH (CODIN)

NCT06588699
View directory record Official record
Conditions
NASH, NAFLD, MASH - Metabolic Dysfunction-Associated Steatohepatitis, Mash, MASH With Fibrosis, MASLD, Fatty Liver Disease, Fatty Liver Disease, Nonalcoholic
Interventions
Digoxin, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 75 Years
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
2
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Oct 21, 2026, 3:43 PM EDT
Completed Phase 2 Interventional Results available

Treating Nonalcoholic Steatohepatitis With Pioglitazone

NCT00062764
View directory record Official record
Conditions
Hepatitis
Interventions
Actos (Pioglitazone)
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 19, 2012 · Synced Oct 21, 2026, 3:43 PM EDT
Completed Not applicable Interventional

Effects of Wolffia Globosa (Mankai) in Patients Undergoing Bariatric Surgery.

NCT03999632
View directory record Official record
Conditions
Bariatric Surgery Candidate, Diet Modification
Interventions
Dietary modification with introduction of Mankai
Other
Lead sponsor
Cleveland Clinic Florida
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Weston, Florida
Source: ClinicalTrials.gov public record
Updated Feb 4, 2021 · Synced Oct 21, 2026, 3:43 PM EDT
Active, not recruiting No phase listed Observational

LITMUS Imaging Study

NCT05479721
View directory record Official record
Conditions
NAFLD, NASH, NASH - Nonalcoholic Steatohepatitis, Fibrosis, Liver, Steatosis of Liver
Interventions
Not listed
Lead sponsor
University of Oxford
Other
Eligibility
18 Years to 100 Years
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 16, 2025 · Synced Oct 21, 2026, 3:43 PM EDT
Completed Phase 2 Interventional

Safety and Tolerability of VK2809 in Patients With Primary Hypercholesterolemia and Non-Alcoholic Fatty Liver Disease

NCT02927184
View directory record Official record
Conditions
Hyperlipidemia, NAFLD
Interventions
VK2809, Placebo
Drug
Lead sponsor
Viking Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
19
States / cities
Chandler, Arizona • Garden Grove, California • Los Angeles, California + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2021 · Synced Oct 21, 2026, 3:43 PM EDT
Terminated Phase 4 Interventional Results available

Metformin for Ectopic Fat Deposition and Metabolic Markers in Polycystic Ovary Syndrome (PCOS)

NCT02500147
View directory record Official record
Conditions
Polycystic Ovary Syndrome, Non-Alcoholic Fatty Liver Disease, Metabolic Syndrome
Interventions
Metformin, Placebo
Drug
Lead sponsor
Columbia University
Other
Eligibility
13 Years to 25 Years · Female only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 2, 2025 · Synced Oct 21, 2026, 3:43 PM EDT
Suspended No phase listed Observational

Longitudinal Study of Mitochondrial Hepatopathies

NCT01148550
View directory record Official record
Conditions
Acute Liver Failure, Mitochondrial Diseases, End Stage Liver Disease, Respiratory Chain Deficiencies, Mitochondrial, Disorder of Fatty Acid Oxidation
Interventions
Not listed
Lead sponsor
Arbor Research Collaborative for Health
Other
Eligibility
Up to 18 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2029
U.S. locations
15
States / cities
Los Angeles, California • San Francisco, California • Aurora, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 21, 2026, 3:43 PM EDT
Completed Phase 2 Interventional

HTD1801 in Adults With Nonalcoholic Steatohepatitis and Liver Fibrosis Who Have Type 2 Diabetes or Pre-Diabetes

NCT05623189
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis (NASH), Type 2 Diabetes
Interventions
HTD1801, Placebo
Drug
Lead sponsor
HighTide Therapeutics (Hong Kong) Limited
Industry
Eligibility
18 Years to 75 Years
Enrollment
218 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
43
States / cities
Chandler, Arizona • Peoria, Arizona • Tucson, Arizona + 36 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 21, 2026, 3:43 PM EDT
Terminated No phase listed Observational

Study Evaluating Metabolic Syndrome in Subjects Undergoing Gastric Bypass Bariatric Syndrome

NCT00283374
View directory record Official record
Conditions
Morbid Obesity, Metabolic Disease
Interventions
Laparoscopic Roux-en-Y Gastric Bypass
Procedure
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
10
States / cities
Irvine, California • Orange, California • Atlanta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated May 18, 2006 · Synced Oct 21, 2026, 3:43 PM EDT
Terminated Phase 2 Interventional Results available

A Study of MK-3655 in Individuals With Pre-cirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-3655-001)

NCT04583423
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis
Interventions
MK-3655, Placebo
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
183 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
48
States / cities
Tucson, Arizona • North Little Rock, Arkansas • Canoga Park, California + 37 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2025 · Synced Oct 21, 2026, 3:43 PM EDT
Withdrawn Phase 1 Interventional

Vitamin E Supplementation in Burn Patients

NCT01413620
View directory record Official record
Conditions
Burn Injury
Interventions
dl-alpha-tocopheryl acetate
Drug
Lead sponsor
Shriners Hospitals for Children
Other
Eligibility
6 Months to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2021
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 21, 2021 · Synced Oct 21, 2026, 3:43 PM EDT
Active, not recruiting Early Phase 1 Interventional

The Gut, Liver And Metabolome in Human Immunodeficiency Virus and Non Alcoholic Fatty Liver Disease

NCT06113003
View directory record Official record
Conditions
HIV, Non-Alcoholic Fatty Liver Disease, Metabolic-Associated Steatotic Liver Disease
Interventions
Prebiotic, Probiotic
Dietary Supplement
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 89 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Oct 21, 2026, 3:43 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Gender and Culturally Specific Approach to Reduce NAFLD in Mexican-American Men

NCT04186260
View directory record Official record
Conditions
NAFLD
Interventions
NAFLD-specific weight loss intervention, Wait-list control
Behavioral · Other
Lead sponsor
University of Arizona
Other
Eligibility
18 Years to 64 Years · Male only
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 24, 2025 · Synced Oct 21, 2026, 3:43 PM EDT
Terminated Phase 2 Interventional Results available

Simtuzumab (SIM, GS-6624) in the Treatment of Cirrhosis Due to NASH

NCT01672879
View directory record Official record
Conditions
Liver Fibrosis Due to NASH
Interventions
Placebo, SIM
Biological
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
259 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
41
States / cities
Phoenix, Arizona • Coronado, California • San Diego, California + 35 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2019 · Synced Oct 21, 2026, 3:43 PM EDT
Completed Phase 1 Interventional Results available

Glycemic Effect of Diazoxide in NAFLD

NCT05729282
View directory record Official record
Conditions
Hyperinsulinemia, Insulin Resistance, Non-Alcoholic Fatty Liver Disease, Prediabetic State
Interventions
Diazoxide oral suspension, 1 mg per kg per dose, Diazoxide oral suspension, 2 mg per kg per dose, Placebo, FreeStyle Libre Pro, Deuterated water (2H2O/D2O)
Drug · Device
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 70 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 21, 2026, 3:43 PM EDT
Terminated No phase listed Observational

Post-Treatment Follow-up Study for Liver Disease Subjects With or Without Cirrhosis After Receiving Emricasan or Placebo

NCT03479125
View directory record Official record
Conditions
Liver Diseases, Liver Fibrosis, Liver Cirrhosis, NASH Fibrosis, Decompensated Non-Alcoholic Steatohepatitis Cirrhosis, Orthotopic Liver Transplantation
Interventions
Ultrasound
Diagnostic Test
Lead sponsor
Conatus Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
3
States / cities
Rialto, California • Tulsa, Oklahoma • Germantown, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 22, 2019 · Synced Oct 21, 2026, 3:43 PM EDT
Recruiting No phase listed Observational

Pathogenesis of Pediatric Nonalcoholic Fatty Liver Disease (NAFLD)

NCT04634643
View directory record Official record
Conditions
NAFLD
Interventions
Usual diet and physical activity
Other
Lead sponsor
Yale University
Other
Eligibility
12 Years to 18 Years
Enrollment
260 participants
Timeline
2021 – 2027
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 21, 2026, 3:43 PM EDT
Active, not recruiting Not applicable Interventional

Non-Invasive Diagnostic Tests for MASLD in Pediatric Population

NCT06218589
View directory record Official record
Conditions
Metabolic Dysfunction Associated Steatotic Liver Disease, Non-Alcoholic Fatty Liver Disease (NAFLD)
Interventions
Velacur, MRI, Blood sample collection for biomarkers, Liver biopsy
Diagnostic Test
Lead sponsor
Emory University
Other
Eligibility
2 Years to 20 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Oct 21, 2026, 3:43 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Preliminary Study to Evaluate Cysteamine Therapy in Human Subjects With Non-Alcoholic Steatohepatitis (NASH)

NCT00799578
View directory record Official record
Conditions
Fatty Liver
Interventions
Cysteamine
Drug
Lead sponsor
Joel Lavine
Other
Eligibility
10 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jan 31, 2014 · Synced Oct 21, 2026, 3:43 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effects of High-Intensity Interval Training Exercise in Adolescents With Hepatosteatosis

NCT04342390
View directory record Official record
Conditions
Non-Alcoholic Fatty Liver Disease, Insulin Resistance, High Intensity Interval Training, Childhood Obesity
Interventions
High-Intensity Interval Training (HIIT)
Other
Lead sponsor
Arkansas Children's Hospital Research Institute
Other
Eligibility
13 Years to 18 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
2
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Aug 22, 2024 · Synced Oct 21, 2026, 3:43 PM EDT
Active, not recruiting No phase listed Observational

Accurate Point of Care Liver Disease Diagnostics

NCT05986916
View directory record Official record
Conditions
NAFLD, Nonalcoholic Fatty Liver
Interventions
Liverscope® exam, MR exam, FibroScan® exam (optional), Blood draw, Body measurements, Questionnaires
Diagnostic Test · Other
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Oct 23, 2025 · Synced Oct 21, 2026, 3:43 PM EDT
Recruiting Phase 2 Interventional

A Study to Test Whether BI 3802876 is Tolerated in People With Compensated Liver Cirrhosis Due to Metabolic Dysfunction- Associated Steatohepatitis (MASH)

NCT07325526
View directory record Official record
Conditions
Liver Cirrhosis
Interventions
BI 3802876, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
26
States / cities
Chandler, Arizona • Coronado, California • La Mesa, California + 21 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 21, 2026, 3:43 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Relation of Obesity With Frequency of Meals (MST 0557)

NCT00229255
View directory record Official record
Conditions
Obesity, Insulin Resistance, Fatty Liver
Interventions
high frequency of meals, twice a day meals
Other
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years to 45 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 1, 2012 · Synced Oct 21, 2026, 3:43 PM EDT